Author:
Beal Eliza W.,Ahmed Ahmed,Grotz Travis,Leiting Jennifer,Fournier Keith F.,Lee Andrew J.,Dineen Sean,Dessureault Sophie,Baumgartner Joel M.,Veerapong Jula,Clarke Callisia,Strong Erin,Maithel Shishir K.,Zaidi Mohammad Y.,Patel Sameer,Dhar Vikrom,Hendrix Ryan,Lambert Laura,Johnston Fabian,Fackche Nadege,Raoof Mustafa,LaRocca Christopher,Ronnekleiv-Kelly Sean,Pokrzywa Courtney,Pawlik Timothy M.,Abdel-Misih Sherif,Cloyd Jordan M.
Reference10 articles.
1. Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; Survival benefit at considerable morbidity and mortality;Votanopoulos;Ann Surg Oncol,2013
2. Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery ( CRS ) and hyperthermic intraperitoneal chemotherapy (HIPEC);Cummins,2016
3. Drugs , Doses , and Durations of Intraperitoneal Chemotherapy : Standardising HIPEC and EPIC for Colorectal , Appendiceal , Gastric , Ovarian Peritoneal Surface Malignancies and Peritoneal Mesothelioma;Lemoine,2017
4. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade Appendiceal carcinoma and extensive peritoneal carcinomatosis;El Halabi;Ann Surg Oncol,2011
5. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy;Klaver;Eur J Surg Oncol,2012